Abstract
Purpose To evaluate the diagnostic value of symptoms used in the screening approaches by daycares and schools for identifying children and adolescents with possible SARS-CoV-2 infection, we designed a large observational study utilizing the data from primary care settings.
Methods This cohort study included children and adolescents evaluated in a network of clinics in Rhode Island. Participants were age-stratified: 0-4, 5-11, and 12-17 years. We estimated the sensitivity, specificity, and area under the receiver operating curve (AUC) of individual symptoms and three symptom combinations: a probable case definition published by the Rhode Island Department of Health (RIDOH), and two novel combinations generated by different statistical approaches to maximize sensitivity and AUC. We evaluated the test characteristics of symptom combinations both with and without consideration of COVID-19 exposure.
Results Two-hundred seventeen (39.1%) of 555 participants were SARS-CoV-2-infected. Fever was more common among 0-4 years-olds (p=0.002); older children more frequently reported fatigue (p=0.02) and anosmia or ageusia (p=0.047). In children >5 years old, anosmia or ageusia had 94-98% specificity. In all age groups, exposure history most accurately predicted infection. In combination with COVID-19 exposure history, various symptom combinations had sensitivity >95% but specificity <30%. No individual symptom or symptom combination had AUC ≥0.70.
Conclusions Anosmia or ageusia in children ≥5 years old and dyspnea in children 5-11 years old should raise providers’ index of suspicion for COVID-19. However, our overall findings underscore the limited diagnostic value of symptoms and the critical need for widely available, efficient testing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PCHC Human Subjects Review Committee approved this study and waived informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Deidentified individual participant data will not be made available.
Abbreviations
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- COVID-19
- coronavirus disease 2019
- RT-PCR
- reverse transcriptase polymerase chain reaction
- NH
- non-Hispanic
- BMI
- body mass index
- CART
- combination generated by classification and regression tree
- IQR
- interquartile range
- AUC
- area under the receiver operating curve